Skip to main content
. Author manuscript; available in PMC: 2018 Jun 19.
Published in final edited form as: AIDS Patient Care STDS. 2017 Oct;31(10):413–420. doi: 10.1089/apc.2017.0133

Table 1.

Baseline Demographic and Behavioral Characteristics of Adult HIV Patients (N= 26,752) Who Initiated ART in 2012

Variables Baseline CD4+ count in cells/μL, n (%)
200–349 (n = 20,827) 350–499 (n = 4336) ≥500 (n = 1589)
Sex
 Male 18,256 14,553 (69.88)  2673 (61.65)  1030 (64.82)
 Female 8496    6274 (30.12)  1663 (38.35)    559 (35.18)
Age at start of ART (years)
 Mean (std.) 39.21 (12.91) 37.89 (11.78) 36.19 (11.06)
 15–44 19,371 14,795 (71.04)  3300 (76.11)  1276 (80.30)
 45–59 5184    4276 (20.05)    768 (17.71)    240 (15.10)
 ≥60 2197    1856 (8.91)    268 (6.18)      73 (4.59)
Marital statusa
 Married or living with partners 16,173 12,039 (58.04)  2944 (68.02)  1190 (75.03)
 Single, divorced or windowed 10,483    8703 (41.96)  1384 (31.98)    996 (24.97)
HIV transmission mode
 MSM 4945    4383 (21.04)    463 (10.68)      99 (6.23)
 Heterosexual 16,142 12,444 (59.75)    2750 (63.42)    948 (59.66)
 IDU 3559    2444 (11.73)    737 (17.00)    378 (23.79)
 Othersb 2106    1556 (7.47)    386 (8.90)    164 (10.32)
Type of treatment center
 County or higher level hospital 24,220 18,945 (90.96)  3842 (88.61)  1433 (90.18)
 Township hospital 2532 1882 (9.04)    494 (11.39)    156 (9.82)
Initial ART regimen
 AZT/d4T+3TC+EFV/NVP 21,414 17,397 (83.53)  3119 (71.93)    898 (56.51)
 TDF +3TC+EFV/NVP 5338    3430 (16.47)  1217 (28.07)    691 (43.49)

All demographic and behavioral characteristics included were shown to be statistically significant with respect to differences between the three treatment groups.

a

Some of the individual counts do not sum to the totals due to missing data.

b

“Others” indicate that the marital status of participants is unknown.

3TC, lamivudine; ART, antiretroviral therapy; AZT, zidovudine; d4T, stavudine; EFV, efavirenz; IDU, injection drug use; MSM, men who have sex with men; NVP, nevirapine; TDF, tenofovir.